Showing results (101-110 of 145) with videos related to

Sort By:
Pageof 15
Multiple Sclerosis (Houndmills, Basingstoke, England)|July 7, 2025
Four years on: Pregnancy and birth outcomes reported in the MSBase pregnancy, neonatal outcomes, and Women's Health Registry (2020-2024)Vilija G Jokubaitis, Raed Alroughani, Ayse Altintas, et al.
Computer Methods and Programs in Biomedicine|June 19, 2021
Longitudinal machine learning modeling of MS patient trajectories improves predictions of disability progressionEdward De Brouwer, Thijs Becker, Yves Moreau, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|April 4, 2022
Multiple Sclerosis Severity Score (MSSS) improves the accuracy of individualized prediction in MSTomas Kalincik, Ilya Kister, Tamar E Bacon, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|October 29, 2025
Moderate-high efficacy disease-modifying therapies reduce relapse risk in late-onset multiple sclerosisYi Chao Foong, Daniel Merlo, Melissa Gresle, et al.
Therapeutic Advances in Neurological Disorders|November 11, 2024
The impact of COVID-19 infection on multiple sclerosis disease course across 12 countries: a propensity-score-matched cohort studyDavid Levitz, Yi Chao Foong, Paul Sanfilippo, et al.
Computer Methods and Programs in Biomedicine|February 18, 2025
Explainable time-to-progression predictions in multiple sclerosisRobbe D'hondt, Klest Dedja, Sofie Aerts, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|January 15, 2019
Comparison of fingolimod, dimethyl fumarate and teriflunomide for multiple sclerosisTomas Kalincik, Eva Kubala Havrdova, Dana Horakova, et al.
JAMA Neurology|June 5, 2023
Comparison Between Dimethyl Fumarate, Fingolimod, and Ocrelizumab After Natalizumab CessationChao Zhu, Tomas Kalincik, Dana Horakova, et al.
Brain : a Journal of Neurology|September 18, 2020
Delay from treatment start to full effect of immunotherapies for multiple sclerosisIzanne Roos, Emmanuelle Leray, Federico Frascoli, et al.
Multiple Sclerosis and Related Disorders|August 2, 2022
Severity of COVID19 infection among patients with multiple sclerosis treated with interferon-βSteve Simpson-Yap, Ashkan Pirmani, Edward De Brouwer, et al.
Pageof 15